2XTB image
Deposition Date 2010-10-05
Release Date 2011-06-29
Last Version Date 2024-05-08
Entry Detail
PDB ID:
2XTB
Keywords:
Title:
Crystal Structure of Trypanosoma brucei rhodesiense Adenosine Kinase Complexed with Activator
Biological Source:
Source Organism:
Host Organism:
Method Details:
Experimental Method:
Resolution:
2.80 Å
R-Value Free:
0.29
R-Value Work:
0.23
R-Value Observed:
0.23
Space Group:
P 41 21 2
Macromolecular Entities
Structures with similar UniProt ID
Protein Blast
Polymer Type:polypeptide(L)
Molecule:ADENOSINE KINASE
Gene (Uniprot):Tb06.4M18.780
Chain IDs:A
Chain Length:347
Number of Molecules:1
Biological Source:TRYPANOSOMA BRUCEI RHODESIENSE
Ligand Molecules
Primary Citation
Crystal Structures of T. B. Rhodesiense Adenosine Kinase Complexed with Inhibitor and Activator: Implications for Catalysis and Hyperactivation.
Plos Negl Trop Dis 5 E1164 ? (2011)
PMID: 21629723 DOI: 10.1371/JOURNAL.PNTD.0001164

Abstact

BACKGROUND The essential purine salvage pathway of Trypanosoma brucei bears interesting catalytic enzymes for chemotherapeutic intervention of Human African Trypanosomiasis. Unlike mammalian cells, trypanosomes lack de novo purine synthesis and completely rely on salvage from their hosts. One of the key enzymes is adenosine kinase which catalyzes the phosphorylation of ingested adenosine to form adenosine monophosphate (AMP) utilizing adenosine triphosphate (ATP) as the preferred phosphoryl donor. METHODS AND FINDINGS Here, we present the first structures of Trypanosoma brucei rhodesiense adenosine kinase (TbrAK): the structure of TbrAK in complex with the bisubstrate inhibitor P(1),P(5)-di(adenosine-5')-pentaphosphate (AP5A) at 1.55 Å, and TbrAK complexed with the recently discovered activator 4-[5-(4-phenoxyphenyl)-2H-pyrazol-3-yl]morpholine (compound 1) at 2.8 Å resolution. CONCLUSIONS The structural details and their comparison give new insights into substrate and activator binding to TbrAK at the molecular level. Further structure-activity relationship analyses of a series of derivatives of compound 1 support the observed binding mode of the activator and provide a possible mechanism of action with respect to their activating effect towards TbrAK.

Legend

Protein

Chemical

Disease

Primary Citation of related structures